Alzheimer's disease (AD) presents limited options for decelerating clinical deterioration. Lecanemab (BAN2401) is a humanized IgG1 monoclonal antibody that specifically targets soluble amyloid-beta (Aβ) protofibrils, known for their role in plaque formation and neurotoxicity. Preclinical and early phase studies indicate its potential for amyloid clearance and clinical benefits.

Study Design

Clarity AD Trial:

• Type: Multicenter, randomized, double-blind, placebo-controlled phase 3 trial.
• Population: Adults aged 50-90 with early symptomatic AD (mild cognitive impairment or mild dementia) and confirmed amyloid pathology via PET or CSF biomarkers.
• Intervention: Lecanemab 10 mg/kg IV every 2 weeks compared to placebo for 18 months.
• Primary Outcome: Change from baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months.
• Key Secondary Outcomes: Changes in cognition and function measured by ADAS-Cog14, ADCOMS, ADCS-MCI-ADL, and brain amyloid burden on PET.

Primary Results

• Cognitive & Functional Decline: Lecanemab significantly slowed decline versus placebo on the CDR-SB at 18 months.
• Magnitude of Effect: The treatment arm showed a 27% reduction in clinical decline compared to placebo.

Interpretation: Patients receiving lecanemab experienced modestly less progression of disease severity over 18 months in both cognitive and functional measures.

Biomarker and Mechanistic Findings

• Amyloid PET: Significant reductions in amyloid plaque burden were observed in the lecanemab group compared to placebo at all time points.
• Downstream Markers: Improvements in tau biomarkers (e.g., CSF/plasma p-tau181) and other indices suggest an impact on AD pathophysiology beyond amyloid removal.

Safety Profile

• Amyloid-Related Imaging Abnormalities (ARIA):
  • ARIA-E (edema) and ARIA-H (microhemorrhages) were more frequent with lecanemab than placebo.
  • Most events were asymptomatic or transient, with rare symptomatic cases (e.g., headache, confusion).
• Other Adverse Events: Infusion-related reactions and mild to moderate neurologic symptoms occurred at low rates consistent with class effects.

Clinical Implications

Efficacy:
Lecanemab is among the first disease-modifying therapies shown in a large phase 3 AD trial to slow clinical decline and significantly reduce brain amyloid burden in early AD. The clinical benefit is modest but statistically robust, supporting anti-amyloid immunotherapy as a viable strategy in appropriately selected patients.

Patient Selection:

• Best evidence of benefit is in patients with early symptomatic disease and confirmed amyloid pathology.
• Efficacy in later stages of AD is not yet established.

Risk/Benefit:
ARIA is the main safety concern, necessitating MRI monitoring and clinical vigilance during therapy.

Regulatory and Practice Context

• Lecanemab (brand name Leqembi) has been approved in multiple jurisdictions for adults with mild cognitive impairment or mild dementia due to AD with confirmed amyloid pathology.
• Long-term open-label extensions indicate sustained effects on clinical progression, with safety profiles consistent with core trial findings.

Limitations and Future Directions

• Clinical Relevance vs Statistical Significance: The clinical meaningfulness of the modest slowed decline is debated, particularly in diverse clinical populations and APOE ε4 subgroups.
• Longer Follow-Up: Extended outcomes beyond 18 months will help characterize the durability of benefit and long-term safety.
• Combination Therapies: Combining with tau-targeting agents and multi-pathway approaches may enhance the therapeutic impact.

Conclusion

The NEJM Clarity AD trial provides substantial evidence that targeting soluble Aβ protofibrils with lecanemab slows biomarker progression and clinical decline in early Alzheimer's disease, marking a significant advance in disease-modifying therapy for AD, with careful consideration of safety and patient selection.

...